172 related articles for article (PubMed ID: 29325144)
1. A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
Moore SC; Playdon MC; Sampson JN; Hoover RN; Trabert B; Matthews CE; Ziegler RG
J Natl Cancer Inst; 2018 Jun; 110(6):588-597. PubMed ID: 29325144
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the Role of Circulating Unconjugated Estradiol in Mediating the Body Mass Index-Breast Cancer Association.
Schairer C; Fuhrman BJ; Boyd-Morin J; Genkinger JM; Gail MH; Hoover RN; Ziegler RG
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):105-13. PubMed ID: 26637268
[TBL] [Abstract][Full Text] [Related]
3. Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort.
Jobard E; Dossus L; Baglietto L; Fornili M; Lécuyer L; Mancini FR; Gunter MJ; Trédan O; Boutron-Ruault MC; Elena-Herrmann B; Severi G; Rothwell JA
Br J Cancer; 2021 May; 124(10):1734-1743. PubMed ID: 33723391
[TBL] [Abstract][Full Text] [Related]
4. The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium.
Guida F; Tan VY; Corbin LJ; Smith-Byrne K; Alcala K; Langenberg C; Stewart ID; Butterworth AS; Surendran P; Achaintre D; Adamski J; Amiano P; Bergmann MM; Bull CJ; Dahm CC; Gicquiau A; Giles GG; Gunter MJ; Haller T; Langhammer A; Larose TL; Ljungberg B; Metspalu A; Milne RL; Muller DC; Nøst TH; Pettersen Sørgjerd E; Prehn C; Riboli E; Rinaldi S; Rothwell JA; Scalbert A; Schmidt JA; Severi G; Sieri S; Vermeulen R; Vincent EE; Waldenberger M; Timpson NJ; Johansson M
PLoS Med; 2021 Sep; 18(9):e1003786. PubMed ID: 34543281
[TBL] [Abstract][Full Text] [Related]
5. Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer.
Guertin KA; Loftfield E; Boca SM; Sampson JN; Moore SC; Xiao Q; Huang WY; Xiong X; Freedman ND; Cross AJ; Sinha R
Am J Clin Nutr; 2015 May; 101(5):1000-11. PubMed ID: 25762808
[TBL] [Abstract][Full Text] [Related]
6. Prospective analysis of circulating metabolites and breast cancer in EPIC.
His M; Viallon V; Dossus L; Gicquiau A; Achaintre D; Scalbert A; Ferrari P; Romieu I; Onland-Moret NC; Weiderpass E; Dahm CC; Overvad K; Olsen A; Tjønneland A; Fournier A; Rothwell JA; Severi G; Kühn T; Fortner RT; Boeing H; Trichopoulou A; Karakatsani A; Martimianaki G; Masala G; Sieri S; Tumino R; Vineis P; Panico S; van Gils CH; Nøst TH; Sandanger TM; Skeie G; Quirós JR; Agudo A; Sánchez MJ; Amiano P; Huerta JM; Ardanaz E; Schmidt JA; Travis RC; Riboli E; Tsilidis KK; Christakoudi S; Gunter MJ; Rinaldi S
BMC Med; 2019 Sep; 17(1):178. PubMed ID: 31547832
[TBL] [Abstract][Full Text] [Related]
7. Oxidative Stress and Breast Cancer Risk in Premenopausal Women.
Nichols HB; Anderson C; White AJ; Milne GL; Sandler DP
Epidemiology; 2017 Sep; 28(5):667-674. PubMed ID: 28520645
[TBL] [Abstract][Full Text] [Related]
8. Validation of plasma metabolites associated with breast cancer risk among Mexican Americans.
Zhao H; Shen J; Ye Y; Wu X; Esteva FJ; Tripathy D; Chow WH
Cancer Epidemiol; 2020 Dec; 69():101826. PubMed ID: 33010726
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and serum proteomic profile in breast cancer and healthy women: a prospective study.
Garrisi VM; Tufaro A; Trerotoli P; Bongarzone I; Quaranta M; Ventrella V; Tommasi S; Giannelli G; Paradiso A
PLoS One; 2012; 7(11):e49631. PubMed ID: 23226214
[TBL] [Abstract][Full Text] [Related]
10. Weight Fluctuation and Postmenopausal Breast Cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study.
Komaroff M
J Obes; 2016; 2016():7168734. PubMed ID: 26953120
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
Dougan MM; Li Y; Chu LW; Haile RW; Whittemore AS; Han SS; Moore SC; Sampson JN; Andrulis IL; John EM; Hsing AW
BMC Cancer; 2018 May; 18(1):532. PubMed ID: 29728083
[TBL] [Abstract][Full Text] [Related]
12. Urinary prostaglandin E2 metabolite and breast cancer risk.
Cui Y; Shu XO; Gao YT; Cai Q; Ji BT; Li HL; Rothman N; Wu J; Yang G; Xiang YB; Zheng W
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2866-73. PubMed ID: 25214156
[TBL] [Abstract][Full Text] [Related]
13. Diet-Related Metabolomic Signature of Long-Term Breast Cancer Risk Using Penalized Regression: An Exploratory Study in the SU.VI.MAX Cohort.
Lécuyer L; Dalle C; Lefevre-Arbogast S; Micheau P; Lyan B; Rossary A; Demidem A; Petera M; Lagree M; Centeno D; Galan P; Hercberg S; Samieri C; Assi N; Ferrari P; Viallon V; Deschasaux M; Partula V; Srour B; Latino-Martel P; Kesse-Guyot E; Druesne-Pecollo N; Vasson MP; Durand S; Pujos-Guillot E; Manach C; Touvier M
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):396-405. PubMed ID: 31767565
[TBL] [Abstract][Full Text] [Related]
14. Prospective Investigation of Serum Metabolites, Coffee Drinking, Liver Cancer Incidence, and Liver Disease Mortality.
Loftfield E; Rothwell JA; Sinha R; Keski-Rahkonen P; Robinot N; Albanes D; Weinstein SJ; Derkach A; Sampson J; Scalbert A; Freedman ND
J Natl Cancer Inst; 2020 Mar; 112(3):286-294. PubMed ID: 31168595
[TBL] [Abstract][Full Text] [Related]
15. Plasma metabolites associated with colorectal cancer: A discovery-replication strategy.
Geijsen AJMR; Brezina S; Keski-Rahkonen P; Baierl A; Bachleitner-Hofmann T; Bergmann MM; Boehm J; Brenner H; Chang-Claude J; van Duijnhoven FJB; Gigic B; Gumpenberger T; Hofer P; Hoffmeister M; Holowatyj AN; Karner-Hanusch J; Kok DE; Leeb G; Ulvik A; Robinot N; Ose J; Stift A; Schrotz-King P; Ulrich AB; Ueland PM; Kampman E; Scalbert A; Habermann N; Gsur A; Ulrich CM
Int J Cancer; 2019 Sep; 145(5):1221-1231. PubMed ID: 30665271
[TBL] [Abstract][Full Text] [Related]
16. Application of Metabolomics to Epidemiologic Studies of Breast Cancer: New Perspectives for Etiology and Prevention.
His M; Gunter MJ; Keski-Rahkonen P; Rinaldi S
J Clin Oncol; 2024 Jan; 42(1):103-115. PubMed ID: 37944067
[TBL] [Abstract][Full Text] [Related]
17. Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer.
Patuleia SIS; Hagenaars SC; Moelans CB; Ausems MGEM; van Gils CH; Tollenaar RAEM; van Diest PJ; Mesker WE; van der Wall E
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):441-449. PubMed ID: 33082203
[TBL] [Abstract][Full Text] [Related]
18. Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
Lasky-Su JA; Zeleznik OA; Eliassen AH
J Natl Cancer Inst; 2018 Jun; 110(6):547-548. PubMed ID: 29325156
[No Abstract] [Full Text] [Related]
19. Serum Metabolomic Profiling of All-Cause Mortality: A Prospective Analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Cohort.
Huang J; Weinstein SJ; Moore SC; Derkach A; Hua X; Liao LM; Gu F; Mondul AM; Sampson JN; Albanes D
Am J Epidemiol; 2018 Aug; 187(8):1721-1732. PubMed ID: 29390044
[TBL] [Abstract][Full Text] [Related]
20. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Hershman DL; Unger JM; Crew KD; Till C; Greenlee H; Minasian LM; Moinpour CM; Lew DL; Fehrenbacher L; Wade JL; Wong SF; Fisch MJ; Lynn Henry N; Albain KS
J Natl Cancer Inst; 2018 Jun; 110(6):669-676. PubMed ID: 29361042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
